Japan virus covid-19 RNA Government Japan

Fujifilm boosts production capacity for potential Covid-19 drug Avigan

Reading now: 121
www.pharmaceutical-technology.com

Japan’s Fujifilm has expanded manufacturing capacity to boost production of its influenza drug Avigan (favipiravir), being assessed to potentially treat Covid-19.

Capacity is being increased at the company’s Fujifilm Wako Pure Chemical facility in Japan. This facility will produce pharmaceutical intermediates required to manufacture Avigan.

Fujifilm estimates to increase monthly production of the drug up to 100,000 treatment courses by July, said to be nearly 2.5 times higher compared to the beginning of March.

The production will then be increased to 300,000 treatment courses by September. One treatment course with the drug involves a 14-day regimen of two 1800mg loading doses each on day one, and two 800mg maintenance doses each on

Read more on pharmaceutical-technology.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA